Company intelligence / Profile preview

Share & Service

Ownership: Private
Development stage: Other

Overview

Share & Service developed EasyBreath, an eight-week customized digital respiratory rehabilitation program delivered via software, approved by the Korean Ministry of Food and Drug Safety in April 2024. The product is designed to improve aerobic capacity and reduce breathlessness for patients with chronic respiratory diseases such as COPD, asthma, and lung cancer. It is one of the first four digital therapeutics authorized in South Korea[2][3].

Therapeutic areas: PulmonologyOncology
Modalities: DeviceDigital therapeutic (software as a medical device)
Industry: Digital Health Medical Devices

Partnerships

Supported by the Korean Ministry of Food and Drug Safety during development and clinical trial design phases[2]

Beyond the preview

Go deeper on Share & Service.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Share & Service.

Explore the full profile